FUNDAMENTALS |
MarketCap: |
0.807 mill
|
EPS: |
-15.64
|
P/E: |
0
|
Earnings Date: |
Apr 23, 2024 |
SharesOutstanding: |
18.98 mill
|
Avg Daily Volume: |
0.0380 mill
|
RATING
2024-04-23 |
B
|
Neutral
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Sell
|
|
DE: |
Strong Sell
|
|
P/E: |
Neutral
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 0 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
N/A
|
Company: PE 0 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0295 - 0.0555
( +/- 30.59%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-11-07 | Bodmer Mark | Buy | 6 625 | Common Stock |
2023-11-08 | Bodmer Mark | Sell | 3 163 | Common Stock |
2023-11-07 | Bodmer Mark | Sell | 6 625 | Restricted Stock Units |
2023-11-07 | Mchale Duncan | Buy | 6 500 | Common Stock |
2023-11-08 | Mchale Duncan | Sell | 3 103 | Common Stock |
INSIDER POWER |
86.67
|
Last
96 transactions |
Buy:
11 679 076 | Sell:
749 652 |
Forecast:
13:17 - $0.0410
Live Trading Signals (every 1 min)
Forecast
1: 11:47 - $0.0420
Forecast 2: 12:37 - $0.0410
Forecast 3: 13:17 - $0.0410
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
Volume Signals |
Price |
$0.0425 (-2.41% )
|
Volume |
0.0014 mill
|
Avg. Vol. |
0.0380 mill
|
% of Avg. Vol |
3.68 %
|
Signal 1: |
|
Signal 2: |
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EVLO
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.